DSM Supporting AREDS Study

December 11, 2006

1 Min Read
DSM Supporting AREDS Study

PARSIPPANY, N.J.—DSM Nutritional Products announced it is supporting the recently announced nationwide Age-Related Eye Disease Study 2 (AREDS2)—coordinated through the National Eye Institute—by providing the lutein, zeaxanthin and omega-3 fatty acid dietary supplements to use in the trial. AREDS2 is designed to refine the findings of the original AREDS study, which found high-dose antioxidant vitamins and minerals could reduce the progression of age-related macular degeneration (AMD). The AREDS2 formulation will include vitamins C and E, beta-carotene, zinc and copper, plus 10 mg of lutein and 2 mg of zeaxanthin, as well as fish oil-based omega-3s.

“This study is very exciting and we believe it may help provide further support on the health benefits of lutein, zeaxanthin and omega-3 fatty acid supplementation and demonstrate their potential to help save the sight of thousands of individuals every year,” said James Elliott, Ph.D., director of nutritional science for DSM (www.nutraaccess.com).

Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.

You May Also Like